AIMI — AIM ImmunoTech Share Price
0.000.00%
Last trade - 00:00- $6.14m
- $4.47m
- $0.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 36.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -388.69% | ||
| Operating Margin | -11630.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.16 | 0.14 | 0.14 | 0.2 | 0.17 | 0.2 | 0.2 | 3.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Directors
- William Mitchell NEC (85)
- Thomas Equels PRE (68)
- Ellen Lintal CFO (62)
- Peter Rodino COO (69)
- David Strayer CSO (74)
- Stewart Appelrouth IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 1990
- Public Since
- July 12th, 1996
- No. of Shareholders
- 146
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 72,290,030
- Address
- 2117 SW Highway 484, OCALA, 34473-7949
- Web
- https://aimimmuno.com/
- Phone
- +1 3524487797
- Contact
- Jenene Thomas
- Auditors
- BDO USA, LLP
Upcoming Events for AIMI
Q2 2025 AIM ImmunoTech Inc Earnings Release
Similar to AIMI
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the AIM ImmunoTech share price?
As of Today at 19:08 UTC, shares in AIM ImmunoTech are trading at $0.09. This share price information is delayed by 15 minutes.
How has the AIM ImmunoTech share price performed this year?
Shares in AIM ImmunoTech last closed at $0.09 and the price had moved by -78.97% over the past 365 days. In terms of relative price strength the AIM ImmunoTech share price has underperformed the S&P500 Index by -80.5% over the past year.
What are the analyst and broker recommendations for AIM ImmunoTech?
The overall consensus recommendation for AIM ImmunoTech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AIM ImmunoTech dividend yield?
AIM ImmunoTech does not currently pay a dividend.
Does AIM ImmunoTech pay a dividend?
AIM ImmunoTech does not currently pay a dividend.
When does AIM ImmunoTech next pay dividends?
AIM ImmunoTech does not currently pay a dividend.
How do I buy AIM ImmunoTech shares?
To buy shares in AIM ImmunoTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AIM ImmunoTech?
As of the previous close price of $0.09, shares in AIM ImmunoTech had a market capitalisation of $6.14m.
Where are AIM ImmunoTech shares listed?
Here are the trading details for AIM ImmunoTech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AIMI
What kind of share is AIM ImmunoTech?
Based on an overall assessment of its quality, value and momentum AIM ImmunoTech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AIM ImmunoTech share price forecast for 2025?
The analyst consensus target price for shares in AIM ImmunoTech is $1.50. That is 1664.71% above the last closing price of $0.09.
Analysts covering AIM ImmunoTech currently have a consensus Earnings Per Share (EPS) forecast of -$0.31 for the next financial year.
Find out moreWhat is the trend in the AIM ImmunoTech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AIM ImmunoTech. Over the past six months, its share price has underperformed the S&P500 Index by -67.36%.
As of the last closing price of $0.09, shares in AIM ImmunoTech were trading -60.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AIM ImmunoTech PE Ratio?
The AIM ImmunoTech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AIM ImmunoTech?
AIM ImmunoTech's management team is headed by:
- William Mitchell - NEC
- Thomas Equels - PRE
- Ellen Lintal - CFO
- Peter Rodino - COO
- David Strayer - CSO
- Stewart Appelrouth - IND